Welcome to our dedicated page for Lumexa Imaging Holdings news (Ticker: LMRI), a resource for investors and traders seeking the latest updates and insights on Lumexa Imaging Holdings stock.
Lumexa Imaging Holdings, Inc. (NASDAQ: LMRI) is a nationwide provider of diagnostic imaging services and outpatient medical imaging in the United States. This news page focuses on company announcements and developments that relate directly to Lumexa’s operations, growth strategy and capital markets activity.
Readers can find coverage of Lumexa Imaging’s expansion of its outpatient imaging center network, including de novo openings in high-growth metropolitan statistical areas. For example, the company has reported record de novo expansion, opening new centers in states such as South Carolina, North Carolina, New York and Texas, and increasing its total to more than 185 centers across 13 states. News items also highlight Lumexa’s positioning as one of the nation’s largest providers of outpatient imaging services and its role as a partner to health systems and radiologists.
This page also aggregates Lumexa Imaging’s capital markets and investor-related news, such as announcements about its initial public offering on the Nasdaq Global Select Market and participation in major healthcare investor conferences. These updates provide context on how the company finances its growth, interacts with investors and communicates its strategy to the market.
By following this LMRI news feed, users can review company-issued press releases on topics such as network expansion, joint venture partnerships with health systems, investor conference appearances and other material events disclosed to the public. The news archive offers a focused view of how Lumexa Imaging is developing its outpatient imaging platform and engaging with the broader healthcare and investment communities over time.
Lumexa Imaging (NASDAQ: LMRI) appointed Kyle Lynch as Chief Growth Officer, effective April 20, 2026. Lynch will lead enterprise growth via joint ventures, acquisitions, and de novo development and oversee opportunity origination, transaction execution, and post-close value realization.
He will also lead the Sales Center of Excellence to standardize metrics, boost sales productivity, and drive referral and same-center performance across Lumexa Imaging’s national outpatient imaging platform.
Lumexa Imaging (Nasdaq: LMRI) reported preliminary, unaudited fourth-quarter and full-year 2025 results and reiterated 2026 guidance on March 26, 2026. Q4 revenue was $267.7 million, up 7.9% year-over-year, with Adjusted EBITDA of $63.8 million (23.8% margin). Full-year 2025 revenue was $1.023 billion and Adjusted EBITDA was $230.2 million. The company cut leverage from 5.5x to 3.5x and added ten facilities in 2025. 2026 guidance: revenue $1.045–1.097 billion and Adjusted EBITDA $234–242 million; Adjusted EPS $0.71–0.77.
Lumexa Imaging (NASDAQ: LMRI) announced executive participation in three investor conferences in March 2026, including speaker times and formats.
Caitlin Zulla, CEO, and Tony Martin, CFO, will present at Raymond James (3:25pm ET, Mar 2), speak at Leerink fireside chat (8:40am ET, Mar 9), and speak at Barclays fireside chat (3:30pm ET, Mar 10). A webcast and presentation materials will be available at the company investor site.
Lumexa Imaging (NASDAQ: LMRI) announced that Jennifer L. Kemp, MD, Chair of its Center for Quality, was elected to the Radiological Society of North America (RSNA) Board of Directors and will serve as board liaison for government relations.
The company highlights Dr. Kemp's focus on patient-centered care and notes Lumexa's use of Scanslated AI-driven software, which has delivered over 2 million reports to patients and yielded a 99% positive survey response on likelihood to choose Lumexa centers.
Lumexa Imaging (NASDAQ: LMRI) set a company record by opening nine de novo outpatient imaging centers in 2025, including two centers that opened in December in Anderson, South Carolina and Cotswold, North Carolina. With these additions, Lumexa operates more than 185 centers across 13 states. Prior 2025 openings occurred in New York, South Carolina and Texas. Management said the de novo strategy targets high-growth MSAs and intends to continue expansion in 2026.
Lumexa Imaging (NASDAQ: LMRI) announced that CEO Caitlin Zulla and CFO Tony Martin will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, with a presentation scheduled for 7:30 AM PST on Monday, January 12, 2026. A live webcast and presentation materials will be available at the company investor site: https://ir.lumexaimaging.com.
Lumexa Imaging (NASDAQ: LMRI) priced its initial public offering of 25,000,000 shares of common stock at $18.50 per share, with a 30‑day underwriter option for up to 3,750,000 additional shares.
The Common Stock is expected to begin trading on the Nasdaq Global Select Market under the symbol LMRI on December 11, 2025, and the offering is expected to close on December 12, 2025, subject to customary closing conditions. The registration statement on Form S‑1 was declared effective by the SEC on December 10, 2025.